RESTON, Va., March 18, 2020 /PRNewswire/ — As the global Coronavirus crisis grows, consumers are making significant changes to the way they interact with content and advertising across platforms.
As the world adjusts to this new reality, Comscore (NASDAQ: SCOR), a trusted partner for planning, transacting, and evaluating media across platforms, will be providing ongoing updates on shifting consumption trends and the resulting impact on the advertising and media industries.
Comscore’s comprehensive COVID-19 insights hub, which will be updated on a regular basis, can be found here: https://www.comscore.com/Insights/Blog/Media-Consumption-during-the-Coronavirus-Pandemic
Among the key findings from Comscore’s initial research:
About Comscore
Comscore (NASDAQ: SCOR) is the trusted partner for planning, transacting and evaluating media across platforms. With a data footprint that combines digital, linear TV, over-the-top and theatrical viewership intelligence with advanced audience insights, Comscore allows media buyers and sellers to quantify their multiscreen behavior and make business decisions with confidence. A proven leader in measuring digital and linear TV audiences and advertising at scale, Comscore is the industry’s emerging, third-party source for reliable and comprehensive cross-platform measurement. To learn more about Comscore, please visit Comscore.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/comscore-research-reveals-coronavirus-crisis-is-dramatically-impacting-media-consumption-301026202.html
SOURCE Comscore
MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the…
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…